We found that our model generally predicted the correct trends for both immunoglobulins, e.g., downtrend in IgA in response to treatment, and biomarkers related to CRAB (Hypercalcemia, Renal failure, Anemia, and Bone lesions) complications (e.g., calcium, hemoglobin, and creatinine). Here, CD79A is linked to Renal insufficiency.